Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINSS: 48-week randomized double-blind placebo-controlled phase 2 study of iscalimab in Sjogren's syndrome
jRCT2080224883Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of iscalimab in Sjögren's syndrome (6 arms), sponsored by Novartis. Started Sep 2019; status: completed.
02
Drugs
iscalimab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on jRCT2080224883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224883.